{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:54:41Z","timestamp":1790747681395,"version":"4.1.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Neuroendocrine tumors (NETs) are highly vascularized malignancies for which effective treatment options remain limited in the unresectable locally advanced or metastatic setting. Although platinum-based chemotherapy has demonstrated antitumor activity in advanced NETs, evidence supporting its combination with antiangiogenic therapy remains insufficient. In this retrospective study, 85 patients with progressive unresectable locally advanced or metastatic well-differentiated NETs initiated bevacizumab plus XELOX, consisting of bevacizumab at 7.5 mg\/kg and oxaliplatin at 130 mg\/m\u00b2 every 3 weeks, together with capecitabine at 1,000 mg\/m\u00b2 twice daily on days 1\u201314 of each 21-day cycle. Among them, 72 patients who completed at least two treatment cycles and underwent post-baseline radiological evaluations comprised the safety set. The primary endpoint was objective response rate (ORR) by RECIST v1.1, while secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Among the efficacy-evaluable patients, 62 (86.1%) received the regimen as second-line or later systemic therapy. Best responses included complete response (CR) in 1 patient (1.4%), partial response (PR) in 29 (40.3%), stable disease (SD) in 41 (56.9%), and progressive disease (PD) in 1 (1.4%), resulting in an ORR of 41.7% and a DCR of 98.6%. In a conservative sensitivity analysis encompassing all 85 treated patients\u2014treating the 13 non-evaluable patients as non-responders\u2014the ORR was 35.3%. After a median follow-up of 17.2 months, the median PFS was 20.9 months (95% CI, 13.7 months\u2013not reached), with 6-, 12-, and 24-month PFS rates of 84.7%, 69.6%, and 47.3%, respectively. Median OS was not reached, and OS data remained immature. The most frequent any-grade adverse events (AEs) were elevated aspartate aminotransferase (48.6%), anemia (44.4%), lymphopenia and hypoalbuminemia (41.7% each), and hyperglycemia (40.3%), while neutropenia was the most frequent individual grade \u22653 AE (5.6%). No grade \u22653 bevacizumab-specific toxicities were observed. These findings suggest that bevacizumab plus XELOX demonstrates clinically meaningful antitumor activity and a manageable safety profile in advanced NET patients. Given the retrospective and single-arm design, this regimen may represent a potential alternative or sequential treatment option when alkylating-agent\u2013based chemotherapy is unsuitable, whereas prospective comparative studies are warranted to validate these findings and determine its optimal clinical role.<\/jats:p>","DOI":"10.3389\/fendo.2026.1939938","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:56:18Z","timestamp":1790744178000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of bevacizumab plus XELOX in patients with unresectable locally advanced or metastatic neuroendocrine tumors"],"prefix":"10.3389","volume":"17","author":[{"given":"Huike","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijing","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihebali","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-22-0301","article-title":"A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors","volume":"30","author":"Abuzakhm","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13611","article-title":"Efficacy of FOLFOX in patients with aggressive pancreatic neuroendocrine tumors after prior capecitabine\/temozolomide","volume":"26","author":"Al-Toubah","year":"2021","journal-title":"Oncologist"},{"key":"B3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.6004\/jnccn.2021.7017","article-title":"Efficacy and toxicity analysis of capecitabine and temozolomide in neuroendocrine neoplasms","volume":"20","author":"Al-Toubah","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081936","article-title":"Multicenter analysis of treatment outcomes for systemic therapy in well-differentiated grade 3 neuroendocrine tumors (NET G3)","volume":"13","author":"Apostolidis","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-09-0108","article-title":"Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin","volume":"17","author":"Basu","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-184","article-title":"Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study","volume":"14","author":"Berruti","year":"2014","journal-title":"BMC Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.06.042","article-title":"Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of the Spanish Neuroendocrine Tumour Group (GETNE0801)","volume":"49","author":"Castellano","year":"2013","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.3147","article-title":"Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors","volume":"30","author":"Chan","year":"2012","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000439086","article-title":"Streptozocin and 5-fluorouracil for the treatment of pancreatic neuroendocrine tumors: efficacy, prognostic factors, and toxicity","volume":"103","author":"Clewemar Antonodimitrakis","year":"2016","journal-title":"Neuroendocrinology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/sj.bjc.6602245","article-title":"Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression","volume":"92","author":"Couvelard","year":"2005","journal-title":"Br J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0117","article-title":"MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors","volume":"23","author":"Cros","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-20-0227","article-title":"Critical appraisal of MGMT in digestive NET treated with alkylating agents","volume":"27","author":"de Mestier","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2020.02.011","article-title":"Digestive neuroendocrine neoplasms: French intergroup clinical practice guidelines for diagnosis, treatment, and follow-up","volume":"52","author":"de Mestier","year":"2020","journal-title":"Dig Liver Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1159\/000498887","article-title":"Comparison of temozolomide-capecitabine to 5-fluorouracil-dacarbazine in 247 patients with advanced digestive neuroendocrine tumors using propensity score analyses","volume":"108","author":"de Mestier","year":"2019","journal-title":"Neuroendocrinology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000500862","article-title":"Temozolomide alone or combined with capecitabine for the treatment of advanced pancreatic neuroendocrine tumor","volume":"110","author":"de Mestier","year":"2020","journal-title":"Neuroendocrinology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.04.005","article-title":"Streptozocin\/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours","volume":"51","author":"Dilz","year":"2015","journal-title":"Eur J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.10.002","article-title":"Bevacizumab combined with 5-FU\/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial): a phase II non-randomised trial","volume":"50","author":"Ducreux","year":"2014","journal-title":"Eur J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29517","article-title":"Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: comparison of efficacy and search for predictive factors guiding treatment choice","volume":"121","author":"Dussol","year":"2015","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2016.1097","article-title":"Systemic chemotherapy with FOLFOX in metastatic grade 1\/2 neuroendocrine cancer","volume":"6","author":"Faure","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4081\/rt.2013.e35","article-title":"Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors","volume":"5","author":"Ferrarotto","year":"2013","journal-title":"Rare Tumors"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.30.15_suppl.4127","article-title":"Bevacizumab, pertuzumab, and Sandostatin for patients with advanced neuroendocrine cancers [abstract","volume":"30","author":"Firdaus","year":"2012","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","article-title":"Recommendations for management of patients with neuroendocrine liver metastases","volume":"15","author":"Frilling","year":"2014","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1159\/000518650","article-title":"Oxaliplatin and 5-fluorouracil in advanced well-differentiated digestive neuroendocrine tumors: a multicenter national retrospective study from the French Group of Endocrine Tumors","volume":"112","author":"Girot","year":"2022","journal-title":"Neuroendocrinology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31531","article-title":"Somatic overgrowth disorders of the PI3K\/AKT\/mTOR pathway and therapeutic strategies","volume":"172","author":"Keppler-Noreuil","year":"2016","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1159\/000430816","article-title":"Temozolomide in advanced neuroendocrine neoplasms: pharmacological and clinical aspects","volume":"101","author":"Koumarianou","year":"2015","journal-title":"Neuroendocrinology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000000659","article-title":"Oxaliplatin-fluoropyrimidine chemotherapy plus bevacizumab in advanced neuroendocrine tumors: an analysis of two phase II trials","volume":"45","author":"Kunz","year":"2016","journal-title":"Pancreas"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13227","article-title":"FOLFOX-bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors","volume":"35","author":"Lacombe","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022111614","article-title":"TSC2 regulates tumor susceptibility to TRAIL-mediated T-cell killing by orchestrating mTOR signaling","volume":"42","author":"Lin","year":"2023","journal-title":"EMBO J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091561","article-title":"Upfront oxaliplatin-fluoropyrimidine chemotherapy and somatostatin analogues in advanced well-differentiated gastro-entero-pancreatic neuroendocrine tumors","volume":"17","author":"Maratta","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000001593","article-title":"Efficacy and toxicity of 5-fluorouracil-oxaliplatin in gastroenteropancreatic neuroendocrine neoplasms","volume":"49","author":"Merola","year":"2020","journal-title":"Pancreas"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690325","article-title":"Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin","volume":"81","author":"Mitry","year":"1999","journal-title":"Br J Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.10.001","article-title":"Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastrointestinal tract (BETTER trial): a phase II non-randomised trial","volume":"50","author":"Mitry","year":"2014","journal-title":"Eur J Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I","article-title":"Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms","volume":"68","author":"Moertel","year":"1991","journal-title":"Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1053\/j.gastro.2010.07.002","article-title":"Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy","volume":"139","author":"Oberg","year":"2010","journal-title":"Gastroenterology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, and bronchial neuroendocrine neoplasms and neuroendocrine neoplasms of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13443","article-title":"PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC)","volume":"37","author":"Sorbye","year":"2025","journal-title":"J Neuroendocrinol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1159\/000444087","article-title":"Oxaliplatin-based chemotherapy in advanced neuroendocrine tumors: clinical outcomes and preliminary correlation with biological factors","volume":"103","author":"Spada","year":"2016","journal-title":"Neuroendocrinology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.1998.00321.x","article-title":"Expression of vascular endothelial growth factor in digestive neuroendocrine tumours","volume":"32","author":"Terris","year":"1998","journal-title":"Histopathology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235688","article-title":"Metronomic temozolomide and bevacizumab: a safe and effective frontier for treating metastatic neuroendocrine tumors","volume":"15","author":"Unal","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000001950","article-title":"Phase II trial of bevacizumab monotherapy in pancreatic neuroendocrine tumors","volume":"50","author":"Zhu","year":"2021","journal-title":"Pancreas"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1939938\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:56:19Z","timestamp":1790744179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1939938\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":46,"alternative-id":["10.3389\/fendo.2026.1939938"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1939938","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1939938"}}